News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The company plans to enter the EU markets in FY22
The company is working closely with its six manufacturing partners in India
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The company also plans to register the similar range of products in the neighbouring countries.
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
PEL will explore the PLI scheme and apply if its beneficial.
India business grew 11.8% YoY vs mid-single digit industry growth.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
